ASA404 fails second late-stage lung cancer trial

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 12
Volume 19
Issue 12

Novartis and its partner Antisoma announced that an interim analysis of data from a late-stage trial showed that vadimezam (ASA404) was unlikely to provide any benefit as a second-line treatment for patients with non-small-cell lung cancer. As a result, Novartis indicated that it would halt development of the compound, which was designed to inhibit angiogenesis.

Novartis and its partner Antisoma announced that an interim analysis of data from a late-stage trial showed that vadimezam (ASA404) was unlikely to provide any benefit as a second-line treatment for patients with non-small-cell lung cancer. As a result, Novartis indicated that it would halt development of the compound, which was designed to inhibit angiogenesis.

The ATTRACT-2 study enrolled patients with advanced NSCLC whose disease had progressed after first-line therapy. In ATTRACT-1, ASA404 failed to demonstrate a survival benefit in previously untreated patients with NSCLC when used in combination with chemotherapy.

Articles in this issue
Roche Gains OK in Europe for Rituximab for Maintenance
JAK inhibitor quells symptoms linked to myelofibrosis
E-Charts help track course of febrile events in hematology
E-Charts help track course of febrile events in hematology
Colon Cancer Patients With p.G13D KRAS Mutations See Better Survival With Cetuximab-Based Therapy
Colon Cancer Patients With p.G13D KRAS Mutations See Better Survival With Cetuximab-Based Therapy
Duke Cancer Center Lands Renewal of $30 Million Grant
Even Insured Cancer Patients May Stumble Over Co-pays and Drug Costs
Even Insured Cancer Patients May Stumble Over Co-pays and Drug Costs
New Jersey cancer center features green lobby
New Jersey cancer center features green lobby
Long Constitutional Telomere Length May Serve as Measure for Colon Cancer Risk in Younger Patients
Long Constitutional Telomere Length May Serve as Measure for Colon Cancer Risk in Younger Patients
Short Course of Radiation Therapy Before Total Mesorectal Excision Lowers Local Recurrence Rate
Short Course of Radiation Therapy Before Total Mesorectal Excision Lowers Local Recurrence Rate
Growing number of pts undergo radiotherapy
Low-intensity electric-field Rx boosts chemo in NSCLC
Melanoma: Rose Bengal Scores, Ipilimumab Sees Delay
Melanoma: Rose Bengal Scores, Ipilimumab Sees Delay
Postgastrectomy Patients May Benefit From HP Eradication Rx
Postgastrectomy Patients May Benefit From HP Eradication Rx
Post-lumpectomy RT lowers risk of recurrence
Post-lumpectomy RT lowers risk of recurrence
CMS: Provenge shows evidence of ‘moderate’ benefit
CMS: Provenge shows evidence of ‘moderate’ benefit
Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content
The blood-based test detected 31% of lung cancers 1 year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Blood-Based Screening Test May Increase Preclinical Lung Cancer Detection

Roman Fabbricatore
November 22nd 2025
Article

The blood-based test detected 31% of lung cancers one year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts

Russ Conroy
November 11th 2025
Article

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Ariana Pelosci
November 8th 2025
Article

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.